Drugs / AZD9496
AZD9496
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03236974 | Oct 2017 → Feb 2019 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02780713 | Jun → Sep 2016 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02248090 | Oct 2014 → Jan 2017 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9496 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02780713 ↗ |
| Known as | CPD 30B | ChEMBL registry synonym — accepted as the source's own label CHEMBL3623004 ↗ |
| Known as | SERD | ChEMBL registry synonym — accepted as the source's own label CHEMBL3623004 ↗ |
| Modality | Small molecule | — CHEMBL3623004 ↗ |
| Route | Oral | “AZD9496 administered orally” NCT02248090 ↗ |